Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 113

Targeting CDK2 for cancer therapy

How CDK2 inhibitors halt cancer cell division👇

✅G1 arrest in p16INK4A-high, cyclin E–high tumors (A, left). In tumors with high p16INK4A and cyclin E, catalytic CDK2 inhibitors block phosphorylation of key CDK2 substrates, including RB and nucleolin, and reduce signals from CDK activity sensors. This suppresses E2F transcriptional activity, leading to reduced cyclin A expression and failure to enter S phase. The net result is a G1 cell-cycle arrest, driven by effective shutdown of the RB–E2F axis.

✅4N accumulation when p16INK4A is absent (A, right). In tumors lacking p16INK4A, CDK2 catalytic inhibition alone does not efficiently block RB phosphorylation or early G1 molecular events. Instead, cells continue through S phase and accumulate with 4N DNA content, indicating arrest later in the cycle (post-replication). In this context, adding a CDK4/6 inhibitor can mimic the p16INK4A state, restore RB dephosphorylation, repress E2F, and shift cells toward a G1 arrest, highlighting the importance of dual CDK control of RB.

✅Catalytic inhibition vs genetic depletion of CDK2 (B). Genetic loss of CDK2 is often tolerated because cells can compensate using cyclin A–CDK1 to complete G2/M. In contrast, catalytic CDK2 inhibitors trap CDK2 in inactive complexes with cyclins, which may interfere with normal handoff to CDK1 and other cell-cycle processes. This leads to accumulation of cells with 4N DNA content, reflecting a block after DNA replication.

✅Why the outcomes differ. These findings suggest that CDK2 has roles beyond simple kinase activity—its inactive, cyclin-bound state under catalytic inhibition may disrupt network dynamics differently than complete protein loss. The precise mechanisms of the 4N arrest are still being investigated and may involve defects in S/G2 transitions, replication stress responses, or mitotic entry control.

✅Therapeutic implication. Tumor response to CDK2 inhibitors depends strongly on p16INK4A status, cyclin E levels, and RB pathway integrity. This supports combination strategies (CDK2 + CDK4/6 inhibition) in selected cancers and emphasizes the need for biomarker-guided patient stratification.

Continue reading “Targeting CDK2 for cancer therapy” | >

Dietary methionine mitigates immune-mediated damage by enhancing renal clearance of cytokines

Nutritional strategy to prevent immune-mediated damage.

Excessive immune response with the inflammatory cytokine and chemokine production may lead to tissue damage.

With Yersinia pseudotuberculosis infection in mic, the researchers found that dietary methionine enhances kidney filtration and promotes urinary excretion of inflammatory cytokines during infection and protects against anorexia, wasting, blood-brain barrier dysfunction, and lethality.

Mechanistically, methionine and its metabolite S-adenosyl methionine (SAM) activate renal mTORC1 signaling, promoting renal growth and enhanced glomerular filtration function.

By improving cytokine clearance, this pathway mitigates immune-mediated damage and reveals a nutritional strategy to promote cooperative defenses. sciencenewshighlights ScienceMission https://sciencemission.com/Dietary-methionine

Troha et al. found that dietary methionine enhances kidney filtration and promotes urinary excretion of inflammatory cytokines during infection. By improving cytokine clearance, this pathway mitigates immune-mediated damage and reveals a nutritional strategy to promote cooperative defenses.

Continue reading “Dietary methionine mitigates immune-mediated damage by enhancing renal clearance of cytokines” | >

Engineered nanobodies improve respiratory defenses in preclinical study

In a multi-institutional study published today in Nature Nanotechnology, researchers from The University of Texas MD Anderson Cancer Center reported that engineered bispecific nanobodies successfully strengthened mucosal defenses in the respiratory tract, improving protection against influenza infection and reducing SARS-CoV-2 transmission in vivo.

Wen Jiang, M.D., Ph.D., associate professor of Radiation Oncology, has been researching different nanotechnologies for their potential use in delivering cancer therapies. That research has led to work with Liming Zhou, M.D., a postdoctoral student, and the late Charles Chan, Ph.D., assistant professor of surgery at Stanford Medicine.

Off-grid filtration technology can remove over 99% of nanoplastics smaller than 50 nm

Professor Jeong-Min Baik’s research group of the SKKU School of Advanced Materials Science and Engineering has developed a reusable electrokinetic filtration platform capable of filtering more than 99% of ultrafine nanoplastic particles smaller than 50 nm even under commercial-level high-flow conditions.

Plastic pollution, which has surged in recent years through industrialization and the pandemic era, poses a direct threat to human health. In particular, nanoplastics smaller than 100 nm—thousands of times thinner than a human hair—can readily pass through biological membranes in the body and trigger serious diseases such as immune dysregulation and carcinogenicity.

However, conventional water purification systems have struggled to effectively remove nanoplastics of such small sizes, highlighting technological limitations; studies have even reported the presence of hundreds of thousands of particles in a single bottle of bottled water.

Ultra-thin wireless retinal implant offers hope for safely restoring vision signals

An international research team led by Prof. Dr. Sedat Nizamoğlu from the Department of Electrical and Electronics Engineering at Koç University has developed a next-generation, safe, and wireless stimulation technology for retinal degenerative diseases that cause vision loss.

The study is published in Science Advances.

Nanoparticles That Destroy Disease Proteins Could Unlock New Treatments for Dementia and Cancer

Scientists have developed a new nanoparticle-based strategy that could dramatically expand the range of disease-causing proteins that can be targeted by modern medicine. A newly released perspective in Nature Nanotechnology describes an emerging nanoparticle-based approach designed to remove harm

Regenerating lost lymph nodes with bioengineered tissues

The rising incidence of cancer worldwide has led to an increasing number of surgeries that involve the removal of lymph nodes. Although these procedures play a major role in cancer staging and preventing the spread of malignancies, they sometimes come with severe long-term consequences.

Since lymph nodes do not naturally regenerate once removed, their absence can lead to a condition known as secondary lymphedema. It manifests as chronic swelling, discomfort, and reduced mobility in affected limbs or regions, severely affecting a patient’s quality of life.

/* */